[Exclusive] Spotlight on Blue House-Labor Dialogue Amid Escalating Drug Price Reduction Dispute

Gathering Stakeholder Opinions Amid Growing Controversy
Pace May Be Adjusted in Response to Industry and Labor Opposition

Amid ongoing conflict between the government and the pharmaceutical industry over drug price reduction policies, the Blue House has drawn attention by meeting directly with industry workers to hear their opinions.

According to sources in the pharmaceutical industry and political circles on March 5, Lim Jun, Presidential Secretary for Health and Welfare, and Lee Oknam, Secretary for Labor, met with representatives from the labor sector, including the Korea Federation of Trade Unions Chemical and Pharmaceutical Division, at the Blue House on March 3. They discussed the government’s policy to lower the prices of generic drugs. One participant stated, "We conveyed concerns about the tangible and intangible damages that workers may suffer, including the possibility that a drug price reduction policy could lead to restructuring within the pharmaceutical industry."

The Blue House has not announced a definitive stance on the direction of the policy but has indicated that it will closely review future policies based on feedback from the labor sector and other stakeholders.

The pharmaceutical industry claims that the drug price reduction policy will have a significant impact on the entire sector. They project that if the government’s proposal is implemented, total annual revenue could decrease by up to 3.6 trillion won. Labor organizations argue that this shock will inevitably lead to increased pressure to reduce costs and could also result in reduced investment in research and development, thereby worsening job insecurity. Some analyses suggest that, for small and medium-sized pharmaceutical companies, even a 10% drop in sales could lead to the loss of at least 500 jobs.

The debate over drug price reductions has continued since the end of last year. In November 2025, the Ministry of Health and Welfare announced a plan to reform the drug pricing system by reducing the prices of generic drugs from about 45–53% of the price of original drugs to the 40% range.

The government cited the need to improve the efficiency of the National Health Insurance budget and to normalize the drug pricing structure as the reasons for pursuing these reforms. The government originally planned to submit the reform plan to the National Health Insurance Policy Deliberation Committee this month and implement it in the second half of 2026. However, as both industry and labor organizations have raised objections, discussions have been delayed. The latest meeting of the National Health Insurance Policy Deliberation Committee did not include the relevant agenda.

Some observers analyze that the government is considering various possibilities, including postponing the implementation of the reform plan to some extent, and is thus adjusting the pace of the process. Nevertheless, the government maintains its basic position of pursuing reasonable improvements to the drug pricing system, taking into account the need to promote new drug development and ensure a stable supply of essential medicines.

This content was produced with the assistance of AI translation services.